293 related articles for article (PubMed ID: 31560043)
1. Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype.
Cordes F; Lenker E; Spille LJ; Weinhage T; Bettenworth D; Kessel C; Schmidt HH; Foell D; Varga G
Inflamm Bowel Dis; 2020 Feb; 26(3):391-406. PubMed ID: 31560043
[TBL] [Abstract][Full Text] [Related]
2. Impaired IFN-γ-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients.
Cordes F; Lenker E; Weinhage T; Spille LJ; Bettenworth D; Varga G; Schmidt HH; Foell D
Inflamm Bowel Dis; 2021 May; 27(6):887-901. PubMed ID: 33165509
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils.
Furuya MY; Asano T; Sumichika Y; Sato S; Kobayashi H; Watanabe H; Suzuki E; Kozuru H; Yatsuhashi H; Koga T; Ohira H; Sekine H; Kawakami A; Migita K
Arthritis Res Ther; 2018 Aug; 20(1):196. PubMed ID: 30157949
[TBL] [Abstract][Full Text] [Related]
4. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
Coskun M; Salem M; Pedersen J; Nielsen OH
Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
[TBL] [Abstract][Full Text] [Related]
5. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
6. A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function.
De Vries LCS; Duarte JM; De Krijger M; Welting O; Van Hamersveld PHP; Van Leeuwen-Hilbers FWM; Moerland PD; Jongejan A; D'Haens GR; De Jonge WJ; Wildenberg ME
Inflamm Bowel Dis; 2019 Mar; 25(4):647-660. PubMed ID: 30668755
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
8. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
Danese S; Grisham M; Hodge J; Telliez JB
Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Mitchell TS; Moots RJ; Wright HL
Clin Exp Immunol; 2017 Aug; 189(2):250-258. PubMed ID: 28369741
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte Macrophage Colony-Stimulating Factor-Activated CD39
Weinhage T; Däbritz J; Brockhausen A; Wirth T; Brückner M; Belz M; Foell D; Varga G
Cell Mol Gastroenterol Hepatol; 2015 Jul; 1(4):433-449.e1. PubMed ID: 28210690
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells.
Brand RM; Moore BA; Zyhowski A; Siegel A; Uttam S; Metter EJ; Engstrom J; Brand RE; Biswas N; Whitcomb DC; Binion DG; Schwartz M; McGowan I
Am J Physiol Gastrointest Liver Physiol; 2021 Mar; 320(3):G396-G410. PubMed ID: 33355506
[TBL] [Abstract][Full Text] [Related]
12. The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
Stalder R; Zhang B; Jean Wrobel L; Boehncke WH; Brembilla NC
Exp Dermatol; 2020 Jan; 29(1):71-78. PubMed ID: 31721311
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients.
Lethen I; Lechner-Grimm K; Gabel M; Knauss A; Atreya R; Neurath MF; Weigmann B
Inflamm Bowel Dis; 2023 Dec; ():. PubMed ID: 38142236
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS.
Calama E; Ramis I; Domènech A; Carreño C; De Alba J; Prats N; Miralpeix M
Pulm Pharmacol Ther; 2017 Apr; 43():60-67. PubMed ID: 28087469
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.
Gao W; McGarry T; Orr C; McCormick J; Veale DJ; Fearon U
Ann Rheum Dis; 2016 Jan; 75(1):311-5. PubMed ID: 26353790
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for the treatment of ulcerative colitis.
Izzo R; Bevivino G; Monteleone G
Expert Opin Investig Drugs; 2016 Aug; 25(8):991-7. PubMed ID: 27177233
[TBL] [Abstract][Full Text] [Related]
17. The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction.
Sayoc-Becerra A; Krishnan M; Fan S; Jimenez J; Hernandez R; Gibson K; Preciado R; Butt G; McCole DF
Inflamm Bowel Dis; 2020 Feb; 26(3):407-422. PubMed ID: 31751457
[TBL] [Abstract][Full Text] [Related]
18. Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells.
Zgheib A; Pelletier-Bonnier É; Levros LC; Annabi B
Cytokine; 2013 Aug; 63(2):187-93. PubMed ID: 23688618
[TBL] [Abstract][Full Text] [Related]
19. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
Kubo S; Yamaoka K; Kondo M; Yamagata K; Zhao J; Iwata S; Tanaka Y
Ann Rheum Dis; 2014 Dec; 73(12):2192-8. PubMed ID: 24013646
[TBL] [Abstract][Full Text] [Related]
20. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
